Main Street Capital originates $157.2 million in new or increased private loan commitments in Q3 2026
Bitget2026/10/08 11:01Main Street Capital originated new or increased private-loan commitments of $157.2 million in Q3 2026; funded $162 million of investments. New commitments backed a distributor of medium-voltage cables and accessories, including $30 million first lien term loan financing. Financing also supported a provider of manufacturer representation and power systems integration services, including a $35.2 million first lien term loan. A manufacturer of industrial mixing equipment received a $17.9 million first lien senior secured term loan commitment. Private-loan portfolio stood at about $2.1 billion at cost across 86 companies; 92.6% first lien debt, 7.4% equity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Main Street Capital Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610080700PR_NEWS_USPR_____DA66435) on October 08, 2026, and is solely responsible for the information contained therein.
- Main Street Capital originated new or increased private-loan commitments of $157.2 million in Q3 2026; funded $162 million of investments.
- New commitments backed a distributor of medium-voltage cables and accessories, including $30 million first lien term loan financing.
- Financing also supported a provider of manufacturer representation and power systems integration services, including a $35.2 million first lien term loan.
- A manufacturer of industrial mixing equipment received a $17.9 million first lien senior secured term loan commitment.
- Private-loan portfolio stood at about $2.1 billion at cost across 86 companies; 92.6% first lien debt, 7.4% equity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
